PAR 2.50% 20.5¢ paradigm biopharmaceuticals limited..

FA bagger potential, page-52

  1. 91 Posts.
    lightbulb Created with Sketch. 20
    I'm still struggling to accept the fiftyonecapital report's assumption of 90% success on the phase 2 trial. That's a fairly bold statement.

    The phase 1 trials should have been somewhat expected as similar studies have been done before. Also, i didn't see any mention about any results so far relative to a placebo group.
    In saying that ,I haven't spent a huge amount of time on this so i hope i'm wrong as we can continue to ride the wave. DYOR
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.